Iselin-based Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced the appointment of Elazer Edelman, MD, PhD, to its board of directors. Currently a professor at MIT and Harvard Medical School, Edelman is widely recognized for his vision, leadership and significant, long-term contribution to the advancement of technological innovation. Edelman brings to Echo Therapeutics over 30 years of experience in facilitating medical inventions and clinical implementation.
“We are very excited to have Edelman, one of the most respected and successful leaders in the medical innovation field, join our board of directors. We recruited Elazer to the board of directors for his breadth of experience and history of driving innovation in the complex and dynamic healthcare environment,” said Michael M. Goldberg, MD, chairman of Echo Therapeutics. “Elazer’s extensive research, clinical and medical experience, along with his broad network within industry, will enable him to make a significant and immediate contribution to the future success of Echo.”
“I am very pleased to join Echo’s board of directors and I believe that the company’s continuous glucose monitoring product represents today’s model of bringing new technologies to market in response to unmet medical and public health needs. This technology has the potential to make a tangible impact on quality of life, health and well-being for all individuals in the weight loss and nutrition sectors, not only for those with diabetes,” commented Edelman.